Crossmark

Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1186/s13054-024-04911-5

Published Online: 2024-04-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gatti, Milo

Cojutti, Pier Giorgio

Pea, Federico
License Information

Text and Data Mining valid from 2024-04-16

Version of Record valid from 2024-04-16
More Information

Article History

Received: 2 March 2024

Accepted: 13 April 2024

First Online: 16 April 2024

Declarations

:

: Not applicable.

: All authors approved the final version submitted for publication.

: M.G. reports grants from Angelini S.p.A., outside the submitted work. P.G.C. reports grants from Angelini S.p.A. and Shionogi, outside the submitted work. F.P. has participated in speaker’s bureau for Angelini, BeiGene, Gilead, InfectoPharm, Menarini, MSD, Pfizer, Sanofi-Aventis, Shionogi, and as consultant for Angelini, AdvanzPharma, BeiGene, Gilead, MSD, Pfizer, Shionogi, Viatris, outside the submitted work.

Document is current

Any future updates will be listed below